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Abstract
Nicotine is the primary addictive component of tobacco products and its complex stimulus effects 
are readily discriminated by humans and non-human animals. Previous preclinical research 
investigating directly the nature of the nicotine stimulus has been limited to male rodents. The 
current study began to address this significant gap in the literature by training female and male rats 
to discriminate 0.4 mg/kg nicotine from saline in the discriminated goal-tracking task. In this task, 
access to sucrose was intermittently available on nicotine session. On saline session, intermixed 
with nicotine sessions on separate days, sucrose was not available. Both sexes acquired the 
discrimination as evidenced by increased head entries into the sucrose receptacle (goal-tracking) 
evoked by nicotine. The nicotine generalization curves were also similar between females and 
males. The pharmacological profile of the nicotine stimulus was assessed using substitution and 
targeted combination tests with the following compounds: sazetidine-A, PHA-543613, 
PNU-120596, bupropion, nornicotine, and cytisine. For both sexes, nornicotine fully substituted 
for the nicotine stimulus, whereas sazetidine-A, bupropion, and cytisine produced partial 
substitution. Female and male rats also responded similarly in interaction tests where a 
combination of 1 mg/kg of sazetidine-A plus nicotine or nornicotine shifted the nicotine dose-
effect curve to the left; however, combinations of sazetidine-A plus bupropion or cytisine failed to 
produce this effect. These findings begin to fill a significant gap in our understanding of sex 
differences with respect to the nicotine stimulus and response to therapeutically interesting 
combinations using a model that includes both sexes.
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INTRODUCTION
Smoking is the leading preventable cause of death in the United States, responsible for 
approximately 443,000 deaths annually (CDC, 2008). In spite of well-known health risks, 
nearly 70 million Americans continue to use tobacco products (NIDA, 2012). Most smokers, 
almost 70%, report that they desire to quit smoking (CDC, 2011). Gender can play an 
important role in this tenacious addiction, as well as in the success of smoking cessation 
treatments. Though fewer women smoke than men, the quit attempts of women are less 
likely to be successful compared to male counterparts, and there is increased sensitivity to 
social and behavioral factors related to tobacco use among women [for reviews see Perkins 
(2009) and Schnoll, Patterson, & Lerman (2007)]. There is no doubt that socio-
environmental factors are likely the cause of some of these sex differences. However, the 
potential import of biological factors cannot be ignored (Arnold, 2009; Beery and Zucker, 
2011; Cahill, 2006; Wetherington, 2007). These include the widespread effect of gonadal 
hormones early in development on the organization of the physiology including the nervous 
system, the differential impact of circulating gonadal hormones that vary across the lifespan 
of the individual, and the differential expression of X and Y genes in women and men (i.e., 
sex chromosome effects).
Preclinical models with rodents have also identified sex differences in the effects of nicotine 
further suggesting a biological mechanism for at least some of the differences. For example, 
females were more sensitive than males to the acute locomotor effects of nicotine (Harrod et 
al, 2004; Kanýt et al, 1999). This sex difference in the stimulant effects of nicotine was 
reduced in gonadectomized females (Booze et al, 1999; Kanýt et al, 1999). Further, female 
rats have higher rates of nicotine self-administration in comparison to males (Donny et al, 
2000). Adult female rats also appear to be more sensitive to the reward-enhancing effects of 
nicotine and they will take more nicotine than males when a weak sensory reinforcer also 
follows lever pressing (Chaudhri et al, 2005). Consistent with this observation, in a place 
conditioning tasks, adult female rats were more sensitive than male rats to the conditioned 
rewarding effects of nicotine; evidence of conditioned reward was abolished in 
ovariectomized females (Torres et al, 2009). In the present study, we sought to extend the 
work on sex differences by investigating whether the nature of the nicotine stimulus differed 
between female and male rats.
Over the years, a variety of tasks have been developed to study the interoceptive stimulus 
effects of drugs in rodents and primates (Murray et al, 2011; Stolerman et al, 2009; Wooters 
et al, 2009). These drug discrimination tasks have served as powerful tools for understanding 
the behavioral and neuropharmacological processes of psychoactive substances. For the 
present study, we used the drug discriminated goal-tracking (DGT) task (Besheer et al, 
2004) to study the interoceptive stimulus effects of nicotine. In the DGT task, rats have 
intermittent access to non-contingent liquid sucrose deliveries when given nicotine before 
the session. On intermixed saline sessions, sucrose is not available. A discrimination 
between nicotine and saline develops as evidenced by nicotine differentially evoking goal-
tracking [i.e., “anticipatory” head entries into the site where sucrose was delivered; see 
Boakes (1977) and Farwell and Ayres (1979)]. This discrimination is specific to the 
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pharmacological effect of nicotine and does not reflect a drug vs no drug discrimination 
(Besheer et al, 2004; Murray and Bevins, 2009).
Sex differences involving interoceptive conditioning with the nicotine stimulus have not 
been studied in the DGT task. Further, after an extensive search of the two-lever drug 
discrimination literature (cf. Stolerman et al, 2009; Wooters et al, 2009), we could not find a 
published paper with rodents that used nicotine as the training stimulus and examined 
potential sex differences (cf. Bevins and Charntikov, 2015). The only published sex 
difference involving the nicotine stimulus in rodents that we found was that reported in Jung 
et al. (2000). In that report, male and female rats were trained to discriminate 
pentylenetetrazol from saline. In substitution tests, nicotine prompted less pentylenetetrazol-
like responding in females than males. Albeit limited, this outcome, combined with the work 
from Perkins and colleagues in humans (Perkins, 1999; Perkins et al, 1996), indicates the 
need to better understand the nature of the nicotine stimulus in both sexes.
With this need in mind, the goal of the present study was to begin to fill this gap in the 
scientific literature on nicotine drug discrimination. Table 1 lists the ligands we used to 
better understand the nature of the nicotine stimulus in female and male rats, as well as the 
purported mechanism(s) of each ligand. The ligands were selected because of their action on 
nicotinic acetylcholine receptors [nAChR (e.g., sazetidine-A)] and/or their use in smoking 
cessation (e.g., bupropion). As detailed in the Methods section, we investigated the 
substitution pattern of bupropion, cytisine, nornicotine, sazetidine-A, PNU-120596, and 
PHA-543613 in the DGT task. Based on the results of our substitution tests, we used 
interaction tests to further inform us about pharmacological profile of selected nicotine-like 
ligands. Because there is a significant gap in understanding pharmacology associated with 
sazetidine-A’s nicotine-like stimulus effect, we focused our interaction tests on 
combinations including sazetidine-A with nicotine, bupropion, nornicotine, or cytisine. 
Interaction tests were also used to test the effect of PNU-120596, a positive allosteric 
modulator for the α7 subunit of nicotinic acetylcholine receptors, in a condition of elevated 
cholinergic tone induced by a low nicotine dose.
MATERIALS AND METHODS
Animals
Subjects were young adult male (n=24) and female (n=24) Sprague-Dawley rats from Harlan 
Laboratories (Indianapolis, IN, USA). Males weighed 271–312 g and females weighed 206–
230 g upon arrival. Rats were divided and tested consecutively in two equal sets; 12 rats of 
each sex per replication. They were individually housed in clear polycarbonate cages (48.3 × 
26.7 × 20.3 cm) lined with TEK-Fresh® cellulose bedding (Harlan Laboratories). The 
colony room was on a 12 h light:dark schedule; lights on at 0600. All experiments were 
conducted during the light cycle. Water was freely available in the home cage. Access to 
chow (Harlan Teklad Diet, Harlan Laboratories, KY, USA) was restricted to maintain rats at 
85% of free-feeding body weight. This 85% target was determined by sampling free-feed 
weight for three days after a week of acclimation to our colony. This 85% target weight was 
increased by 2 grams every 4 weeks. Rats were handled for at least 2 min during the 3 days 
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before the start of the experiment. All protocols were approved by the University of 
Nebraska-Lincoln Institutional Animal Care and Use Committee.
Apparatus
Behavioral testing was conducted in commercially available chambers (ENV-008CT, Med 
Associates, St. Albans, VT, USA) measuring 30.5 × 24.1 × 21.0 cm (l × w × h). Each 
chamber was enclosed in a sound- and light-attenuating cubicle equipped with an exhaust 
fan. Each conditioning chamber was constructed of aluminum sidewalls, polycarbonate 
front, back, and ceiling, with a floors constructed of metal rods. A recessed receptacle (5.2 × 
5.2 × 3.8 cm; l × w × d) was centered on one of the sidewalls. The receptacle had a dipper 
arm, when raised, provided access to 0.1 ml of 26% (w/v) sucrose solution. Dipper access 
was monitored by an infrared beam placed 1.2 cm into the receptacle and 3 cm above the 
chamber floor. A second infrared beam that monitored chamber activity was located 4 cm 
above the floor and 14.5 cm from the side wall containing the receptacle. Experimental 
session and collection of beam breaks were controlled using Med Associates interface and 
software (Med-PC for Windows, version IV).
Drugs
(−)-Nicotine hydrogen tartrate and (−)-cytisine [CYT] were purchased from Sigma (St. 
Louis, MO, USA). Bupropion hydrochloride [BUP] was purchased from Toronto Research 
Chemicals (Toronto, ON, Canada). S-(−)-nornicotine fumarate [NOR] was provided by 
Girindus America, Inc. (Cincinnati, OH, USA). PHA-543613 [PHA], sazetidine-A [SAZ-A], 
and PNU-120596 [PNU] were gifts from the National Institute on Drug Abuse (Research 
Triangle Institute, Research Triangle Park, NC, USA). Nicotine doses are reported as free 
base equivalent, whereas all other compounds are reported in salt form. The vehicle, route of 
administration, injection volume, and injection-to-placement interval (IPI) for each 
compound are detailed in Table 1.
Behavioral Procedures
Discrimination Training—Rats were injected with nicotine (0.4 mg/kg, subcutaneous 
[SC]) in the home cage for 3 consecutive days before discrimination training commenced to 
reduce the initial locomotor-suppressant effects of nicotine (Besheer et al, 2004; Bevins et 
al, 2001). In each of 32 daily training sessions, rats were administered nicotine or saline 5 
min before placement in the chamber for the 20-min session. Rats received a pseudorandom 
order of 16 nicotine and 16 saline sessions with the condition that no more than two of the 
same session type (nicotine vs. saline) occurred in a row. On nicotine sessions, there were 36 
deliveries of sucrose with each access limited to 4 sec. The first sucrose delivery occurred 
between 124 and 152 sec from the start of the session with 4 possible start times 
pseudorandomized throughout the training phase. Time between subsequent sucrose 
deliveries ranged from 4 to 80 sec (mean = 25 sec). For intermixed saline sessions, sucrose 
was withheld. Discrimination training, and all remaining phase, was conducted in a dark 
chamber. On one of the training days, two females and ten males had an inappropriate 
program executed during training (i.e., saline day instead of nicotine, or vice versa). These 
rats had 3 extra nicotine and 3 extra saline sessions. To estimate the missing value for each 
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rat for graphing and analyses, the average of the day preceding and the day following the 
error was used.
Testing Protocol—Generalization and substitution testing phases started immediately 
following discrimination training. On the first 4 consecutive days of a 5-day test cycle, rats 
had 2 nicotine and 2 saline training sessions intermixed as described earlier. On day 5, a 4-
min test session occurred in place of a training session; no sucrose was available during this 
test session (Besheer et al, 2004; Murray et al, 2009). Specifics regarding the ligands and 
order of testing are briefly detailed below and represented in Table 1 and Figure 1.
Nicotine Generalization—Across the 2 sets of rats, we determined 4 separate nicotine 
dose-effect curves. Three of the dose-effect curves used the testing protocol described earlier 
(see Table 1 and Figure 1 for timing and doses). Determination of the final nicotine dose-
effect curve used a cumulative dosing regimen (Thompson et al, 1983). In this regimen, rats 
were administered saline, then after the 5-min IPI, there was a 4-min sucrose-free test. Rats 
were removed from the chamber and given 0.025 mg/kg of nicotine. Following the IPI, there 
was another 4-min sucrose-free test. This procedure was repeated with 0.025 (0.05 
cumulative dose), 0.05 (0.1), 0.1 (0.2), and finally 0.2 (0.4) mg/kg nicotine.
Ligand Substitution and Combination Tests—Substitution tests employed the same 
5-day cycle described in the testing protocol section. On the 5th day of the cycle, the 
assigned ligand was administered at the prescribed IPI (Table 1 and Figure 1 include the 
procedural details, doses, and order of testing). All doses were selected from previous 
studies (see Table 1). Testing combinations such as PNU-120596 plus nicotine was as 
described earlier, except on the test day there were two injections at the designated IPIs.
Dependent Measures
For acquisition, we used dipper entry rate per second before the first sucrose delivery, or 
equivalent time during saline sessions. This measure avoids any influence of sucrose access 
in nicotine sessions on our measure of learning. For testing, we used the rate of dipper 
entries per second across the 4-min test session; recall that no sucrose occurred in these 
tests. We kept a rate measure so that the reader could compare the outcome of testing with 
acquisition. To measure general chamber activity, we used the number of center beam brakes 
throughout all the sessions.
Statistical Analyses
To examine acquisition of drug discrimination responding (nicotine vs. saline), three-way 
ANOVAs were performed with Sex as a between-subjects factor and Drug and Session as 
within-subjects factors. Significant interactions were followed by separate ANOVAs and 
LSD tests (see supplementary Table 2). Data from the substitution and generalization tests 
were analyzed using a multilevel approach. Multilevel modeling for repeated measures 
provides a number of advantages when compared to ANOVAs. For example, multilevel 
modeling does not assume that the relation between the covariate and the outcome is the 
same across the groups and thus does not require meeting the assumption of homogeneity. 
Furthermore, unlike ANOVA, multilevel modeling does not assume that the different cases 
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of data were independent and hence can model relations between different outcomes which 
may be inter-related. Finally, multilevel modeling is more robust in dealing with missing 
data or unequal group sizes which is often the case in preclinical animal models.
With these advantages, dose-effect curves from substitution tests and generalization tests 
were analyzed by building a model with a maximum likelihood fit from a baseline that does 
not include any predictors other than an intercept. The model was built by first adding 
predictor 1 (Dose), then predictor 2 (Sex), then predictor 3 (Activity), and finally an 
interaction between predictor 1 and 2 (Dose × Sex). The predictor or an interaction was 
declared significant when its addition improved the model by accounting for significantly 
more variance. The summaries of the model were used to estimate and report contrasts. 
Contrasts were restricted to control comparisons only (i.e., compared to 0 mg/kg control 
dose). Outcome of model comparisons and contrasts for each analysis are shown in 
Supplemental Tables 3 through 5.
RESULTS
Discrimination Training
Set 1—Recall Figure 1 for the progression for each set of rats through the experiment. An 
omnibus ANOVA on acquisition training (see Figure 2A) revealed significant main effects of 
Drug and Session, as well as a significant Sex × Drug and Sex × Drug × Session interactions 
(see Supplemental Table 2 for output of all omnibus ANOVAs). The significant Sex × Drug 
× Session interaction was followed by two-way Sex × Session ANOVA, separately for 
nicotine and saline sessions. For nicotine sessions, there were significant main effects of Sex 
[F(1,22)=5.2, p<0.05] and Session [F(18,384)=14.1, p<0.001], but no Sex × Session 
interaction [F(18,384)=1.1, p=0.31]. On average, male rats had overall higher responding 
than females. However, this difference dissipated by the end of the training (see sessions 15–
19; Figure 2A). For saline sessions, there was a main effect of Session [F(18,384)=9.8, 
p<0.001]; the main effect of Sex and the Sex × Session interaction were not significant 
(Fs≤1.2, ps≥0.5). A one-way ANOVA within each Sex revealed that among females, 
nicotine evoked higher conditioned responding than saline for sessions 5 to 16 [Drug, 
F(1,395)=324.2, p<0.001; Session, F(18,395)=2.8, p<0.001; Drug × Session, F(18,395)=8.4, 
p<0.001; LSD tests]. Likewise, among males, nicotine evoked higher responding on sessions 
5 to 16 [Drug, F(1,395)=457.9, p<0.001; Session, F(18,395)=4.2, p<0.001; Drug × Session, 
F(18,395)=10.7, p<0.001; LSD tests]. In sum, by the end of the acquisition phase, all rats 
reliably discriminated nicotine from saline and the magnitude of responding between female 
and males was similar.
Set 2—An omnibus ANOVA revealed significant main effects of Drug and Session, as well 
as significant Sex × Session and Drug × Session interactions (see Table 2); no other 
interactions were significant. The Sex × Session interaction was not further investigated 
because a comparison that aggregates Drug (nicotine and saline) is not meaningful across 
sessions. Responding on the first nicotine session was lower than saline; this switched, with 
the nicotine stimulus evoking higher conditioned responding than saline for sessions 5 to 16 
(LSD tests on combined means from females and males; Figure 2B; for consistency, data 
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shown for females and males separately). The transient difference between females and 
males in Set 1 was not seen in Set 2 and is consistent with other unpublished data in our 
laboratory. Regardless, the performance of Set 2 at the end of training was comparable to Set 
1 with robust discrimination and similar responding in females and males.
Nicotine Generalization
DEC-1—Conditioned responding significantly differed depending on the Dose 
[χ2(5)=99.63, p<.0001], but not Sex or Activity (for all analyses in this section see 
Supplemental Table 3). There was no Dose × Sex interaction. Contrasts revealed that 0.05, 
0.1, 0.2, and 0.4 mg/kg nicotine evoked higher conditioned responding than saline (Figure 
3A).
DEC-2—Conditioned responding significantly differed depending on the Dose 
[χ2(4)=75.40, p<.0001], but not Sex or Activity. There was no Dose × Sex interaction. 
Contrasts revealed that 0.1 and 0.4 mg/kg nicotine evoked more conditioned responding than 
saline (Figure 3B).
DEC-3—Conditioned responding significantly differed depending on the Dose 
[χ2(4)=86.27, p<.0001], but not Sex or Activity. There was no Dose × Sex interaction. 
Contrasts revealed that 0.05, 0.1, and 0.4 mg/kg nicotine evoked more conditioned 
responding than saline (Figure 3C).
Cumulative DEC—Responding using the cumulative dose-effect method resembled the 
pattern observed with the standard across session approach used to determine DEC-1 to 3. 
Conditioned responding significantly differed depending on the Dose [χ2(4)=71.50, p<.
0001]. The addition of the Sex factor to the model did not meet the criterion for significance 
(p=0.07). There was also no effect of Activity or Dose × Sex interaction. Contrasts revealed 
that 0.1 and 0.4 mg/kg cumulative nicotine doses evoked greater conditioned responding 
than saline (Figure 3D).
DECs comparison—To compare DECs (excluding 0.2 mg/kg dose from the DEC-1), the 
data from DEC-1 to 3 were aggregated and an Order factor with three levels for each DEC 
was appended to the data. There was no differences in conditioned responding between three 
determinations of the nicotine DEC (no effect of Order, p=0.42). In addition, there was no 
interaction with Order as a factor, nor a Dose × Sex interaction. This outcome suggests 
relative stability of responding across experiments and time of determination.
Substitution for the Nicotine Stimulus
Sazetidine-A—Conditioned responding significantly differed depending on the Dose 
[χ2(3)=56.48, p<.0001; for all analytical output in this section see Supplemental Table 4]. 
There was no effect of Sex or Activity, nor was there a Dose × Sex interaction. Contrasts 
revealed that 1.0 and 3.0 mg/kg sazetidine-A evoked higher conditioned responding than 
saline (Figure 4A).
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PHA—Conditioned responding significantly differed depending on the Dose [χ2(3)=9.84, 
p<.05]. There was no effect of Sex or Activity, nor was there a Dose × Sex interaction. 
Contrasts revealed that responding evoked by 3.0 mg/kg PHA was lower than saline (Figure 
4B).
PNU—There was no effect of Dose,Sex, or Activity. There was no significant Dose × Sex 
interaction. Neither dose of PNU evoked responding that differed from saline (Figure 4C).
Bupropion—Conditioned responding significantly differed depending on the Dose 
[χ2(5)=14.73, p<.05]. There was no effect of Sex or Activity, nor was there a Dose × Sex 
interaction. Contrasts revealed that responding evoked by 10, 20, 30, and 60 mg/kg evoked 
greater conditioned responding than saline (Figure 4D).
Nornicotine—Conditioned responding significantly differed depending on the Dose 
[χ2(4)=92.39, p<.0001]. There was no effect of Sex or Activity, nor was there a Dose × Sex 
interaction. Contrasts revealed that responding evoked by 3.0 and 5.6 mg/kg was higher 
saline (Figure 4E).
Cytisine—Conditioned responding significantly differed depending on the Dose 
[χ2(3)=14.21, p<.01] and Sex [χ2(4)=6.49, p<.05]. There was no Dose × Sex interaction 
and there was no effect of Activity. Contrasts revealed that responding for females [b=0.05, 
t(33)=2.78, p=0.008] and males [b=0.02, t(33)=3.11, p=0.003] controlled by 1.0 mg/kg 
cytisine was higher than responding evoked by saline (Figure 4F).
Overall comparison of ligands tested for substitution—To determine whether a 
compound partially or fully substituted for the nicotine stimulus, we compared responding 
evoked by the training dose of nicotine (0.4 mg/kg nicotine; DEC-1 to 3 combined) to the 
dose of each ligand that evoked the highest mean level of responding: 5.6 mg/kg 
nornicotine; 1.0 mg/kg sazetidine-A; 10 mg/kg bupropion; 1.0 mg/kg cytisine; 1.0 mg/kg 
PHA; 1.0 mg/kg of PNU. Because this comparison includes rats from both sets, we used a 
one-way GLM ANOVA with Drug as a between-subjects factor to analyze the data. There 
was a main effect of Drug [F(6, 118)=27.16, p<0.0001]. Only nornicotine fully substituted 
for the nicotine stimulus as responding evoked by the 5.6 mg/kg dose did not differ from that 
evoked by nicotine (Figure 5; Tukey HSD tests). Sazetidine-A, bupropion, and cytisine 
partially substituted for the nicotine stimulus as responding evoked by each of these ligands 
was higher than saline (recall Figure 4), but lower than that controlled by the training dose of 
nicotine (Figure 5; Tukey HSD tests). Responding evoked by PHA or PNU did not substitute 
for the nicotine stimulus as their responding was significantly lower than responding evoked 
by nicotine and that responding did not differ from responding evoked by saline in their 
respective substitution tests (Tukey HSD tests).
Combination Tests
Sazetidine-A (1 mg/kg) + Nicotine—Responding significantly differed depending on 
the Dose [χ2(4)=16.25, p<.01; for all statistical output in this section see Supplemental 
Table 5]. There was no effect of Sex or Activity, nor was there a Dose × Sex interaction. 
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Contrasts revealed that responding evoked by a combination of 1 mg/kg of sazetidine-A and 
0.05, 0.1, or 0.4 mg/kg of nicotine evoked higher conditioned responding than sazetidine-A 
alone (Figure 6A).
Sazetidine-A (1 mg/kg) + Bupropion—Responding significantly differed depending on 
the Dose [χ2(5)=57.15, p<.0001] and Activity [χ2(1)=3.98, p=0.046]. There was no effect 
of Sex, nor was there a Dose × Sex interaction. Contrasts revealed that this combination did 
not enhance conditioned responding. Conversely, responding evoked by a combination of 1 
mg/kg of sazetidine-A and 20, 30, or 60 mg/kg of bupropion evoked lower conditioned 
responding than sazetidine-A alone (Figure 6B). Because it appears that higher doses 
coincide with the decrease in goal-tracking responding, we conducted additional multivariate 
analyses investigating whether there was a Dose × Activity interaction and whether there 
was difference in Activity between each bupropion dose and sazetidine-A alone (0 mg/kg 
bupropion dose; mean comparisons on Activity alone measure). We found that, although 
there was significant Dose × Activity interaction [χ2(1)=12.03, p=0.034], Activity alone at 
any dose from 5–60 mg/kg did not differ from 0 (sazetidine-A 1 mg/kg). Therefore, the 
decrease in goal-tracking at higher doses likely reflects the interaction of pharmacological 
stimulus effect and hyper-locomotor effects at 20 mg/kg dose or hypo-locomotor effects at 
30 and 60 mg/kg (see point size representing activity in Figure 6B).
Sazetidine-A (1 mg/kg) + Nornicotine—Responding significantly differed depending 
on the Dose [χ2(4)=12.35, p<.05]. There was no effect of Sex or Activity, nor was there a 
Dose × Sex interaction. Contrasts revealed that responding evoked by a combination of 1 
mg/kg of sazetidine-A and 3 mg/kg of nornicotine was higher than sazetidine-A alone 
(Figure 6C).
Sazetidine-A (1 mg/kg) + Cytisine—There was no effect of Dose or Sex on responding. 
There was also no Dose × Sex interaction. Although Dose comparisons did not reveal any 
significant differences (Figure 6D), addition of the Activity variable to the statistical model 
indicated a significant effect of Activity on responding [χ2(1)=15.12, p<.001].
Nicotine (0.05 mg/kg) + PNU—There was no effect of Dose or Sex on responding. There 
was also no Dose × Sex interaction. Contrasts did not reveal any significant differences 
(Figure 6E).
DISCUSSION
Since the publication of Bevins and Charntikov (2015), there still remains not a single 
published paper that we can find that has nicotine as the training stimulus and investigates 
potential sex differences. Given this scientific gap, the main purpose of this study was to 
examine the nature of the nicotine stimulus in female and male rats using ligands selected 
for their action on nAChRs and/or their use in smoking cessation (recall Table 1). Overall, 
females and males acquired the discrimination between 0.4 mg/kg nicotine and saline at a 
similar rate. Further, the between session nicotine dose-effect curves were also comparable 
between sexes. Substitution and combination tests overall revealed similar patterns with the 
exception of cytisine. Cytisine evoked nicotine-like responding that was slightly, but 
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significantly, higher for females. Although we did not discover any major differences 
between females and males, this study reflects an important step in understanding the nature 
of the nicotine stimulus in both sexes.
Nicotine primarily exerts its stimulus effects by activating nicotinic acetylcholine receptors 
located in the central nervous system [see Wooters et al (2009) for a review]. Centrally and 
peripherally active nAChR antagonists like mecamylamine block responding controlled by 
the nicotine stimulus (Besheer et al, 2004; Dwoskin et al, 2008; Struthers et al, 2009). In 
contrast, nAChR antagonists that do not readily cross the blood brain barrier (e.g., 
hexamethonium) do not affect responding to the nicotine stimulus (Besheer et al, 2004; 
Kumar et al, 1987). The α4β2-containing nAChRs seem especially important for the 
stimulus effects of nicotine. nAChR agonists with varying specificity for the α4β2-
containing receptors like TC-2559, ABT-594, ABT-418, and A-85380 evoke responding 
comparable to nicotine in substitution tests (Damaj et al, 1995; Goldberg et al, 1989; 
Jutkiewicz et al, 2011; Papke et al, 2007; Reichel et al, 2010). Partial agonists for α4β2-
containing nAChRs like varenicline and cytisine prompt partial to full substitution 
depending on the study (LeSage et al, 2009; Reichel et al, 2010; Smith et al, 2007).
In the present study, we found that that cytisine and sazetidine-A, both ligands with high 
affinity for the α4β2-containing receptors, met our definition of partial substitution for the 
nicotine stimulus. However, the mean level of responding evoked by the cytisine was less 
than half that of sazetidine-A, and less than a third of what was controlled by the training 
dose of nicotine (see Figure 5). Sazetidine-A, is one of the promising drugs for the treatment 
of nicotine dependence. A conference abstract from the Society for Neuroscience is the only 
report known to us of sazetidine-A substitution for the nicotine stimulus (Xiao et al, 2007). 
In vitro electrophysiological assays show that sazetidine-A potently evoked dopamine 
release from neurons expressing nAChRs (Zwart et al, 2008); this effect was blocked by 
dihydro-β-erythroidine and by mecamylamine. Because dopamine release from striatal 
slices is mediated by α4β2- and α6β2-containing receptors (Grady et al, 2007; Mogg et al, 
2004; Salminen, 2004; Smith et al, 2007), these electrophysiological findings suggest the 
involvement of these receptors. Furthermore, Zwart et al (2008) found that the α6 nAChR 
selective antagonist α-CtxMII reduced striatal cell response evoked by sazetidine-A by 
approximately 48%. This effect indicated that sazetidine-A induced dopamine release was 
almost equally mediated by α4β2- and by α6-containing nAChRs. Along with some other 
promising preclinical reports (Johnson et al, 2012; Levin et al, 2010; Rezvani et al, 2010) 
our findings further confirm the treatment potential of sazetidine-A.
In contrast to the heteromeric nAChRs just discussed, the homomeric α7 nAChR does not 
seem to play a role in generation of the stimulus effects of nicotine. For example, α7 nAChR 
agonists GTS-21 and WO 01/60821A1 do not substitute for the nicotine stimulus (Smith et 
al, 2007; Stolerman et al, 2004). Furthermore, pretreatment with the α7 nAChR antagonist 
GTS-21 or methyllycaconitine (MLA) does not alter responding controlled by the nicotine 
stimulus (Brioni et al, 1996; Van Haaren et al, 1999; Struthers et al, 2009; Zaniewska et al, 
2006). Corroborating and extending this past research, we found that neither PNU-120596, a 
positive allosteric modulator for the α7 nAChR, nor PHA-543613, a selective agonist for the 
α7 nAChRs, evoked nicotine-like responding (see later discussion).
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Previous studies report mixed findings with bupropion substitution for the nicotine stimulus: 
full substitution (Wiley et al, 2002; Wilkinson et al, 2009, 2010; Young and Glennon, 2002); 
partial substitution (Desai et al, 2003); no substitution (Shoaib et al, 2003). At this point, 
unidentified procedural differences across studies are likely responsible for different 
outcomes. Our study adds partial substitution in females and males to this list. Recall that 
nicotine-like responding was highest at the 10, 20, 30, and 60 mg/kg doses of bupropion (see 
Figure 4D). Responding was somewhat lower and more variable at the higher doses (20–60 
mg/kg). A likely factor to be considered in this effect is bupropion evoked hyperlocomotion 
that has been previously well documented(Cooper et al, 1980; Nielsen et al, 1986; Wilkinson 
& Bevins, 2007, Wilkinson et al, 2006). In fact, previous exposure to nicotine can enhance 
the subsequent locomotor stimulant effects of bupropion (Wilkinson et al, 2006). However, 
our multivariate analysis does not show a significant contribution of the locomotor activity 
to the dose-dependent variability in our dependent measure – dipper entries. This outcome 
suggests that, at least in the experimental paradigm presented in this study, bupropion’s 
locomotor effects do not interfere with its nicotine-like stimulus effects.
Nornicotine, is an alkaloid found in tobacco products, as well as a minor metabolite of 
nicotine in humans, non-human primates, and rodents (Benowitz, 1991; Ghosheh et al, 
1999). In the brain, nornicotine binds to various combinations of nAChR subunits among 
which it has highest affinity for α6/3β2β3, α7, and α4β2 subunits (α6/3β2β3 > α7 > α4β2 
> α3β4 > α3β2hα5 > α3β2β3 > α3β2; Papke et al, 2007). In the present study, we 
replicated past work showing that nornicotine (3.0 and 5.6 mg/kg) evoked nicotine-like 
responding in male rats (Desai et al, 1999; Goldberg et al, 1989; Reichel et al, 2010) and 
extended this observation to female rats. This substitution was comparable between sexes 
and at the highest dose tested (5.6 mg/kg), responding was statistically similar to the 0.4 
mg/kg training dose of nicotine (i.e., full substitution). In fact, nornicotine was the only 
compound tested that fully substituted for the nicotine stimulus (see Figure 5).
Similar to substitution tests, combination tests can be used to elucidate receptor mechanisms 
contributing to the stimulus effects of nicotine. In the present study, findings from the 
substitution tests, along with the known pharmacological profiles of the ligands, guided our 
selection of drug interaction tests (recall Table 1). Because there is a limited understanding 
of the nicotine-like effects of sazetidine-A, we elected to perform a number of interaction 
tests with sazetidine-A and ligands with known nicotine-like stimulus effects. These types of 
tests are critical to start understanding receptor mechanism underlying sazetidine-A’s 
substitution for the nicotine stimulus and further considering sazetidine-A as a possible 
therapeutic agent. To this end, we tested in females and males the effect of combining 
sazetidine-A with nicotine, bupropion, nornicotine, or cytisine. Notably, only combinations 
of 1 mg/kg sazetidine-A plus nicotine or nornicotine increased nicotine-like responding 
relative to sazetidine-A alone. Enhancement by the low dose of nicotine (0.05 mg/kg) likely 
reflects a summative action of the two compounds on α4β2-containing nAChRs. 
Importantly, we included the higher doses of nicotine (0.1 to 0.4 mg/kg) in the combination 
tests to determine if the partial agonist effect of sazetidine-A would decrease conditioned 
responding evoked by the nicotine stimulus. LeSage and colleagues (2009) found that the 
α4β2 partial agonist varenicline blunted responding to their training dose of nicotine. We, 
however, did not find a similar effect. Rather, these higher doses increased responding 
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relative to sazetidine-A alone. Although the combination tests did not include a nicotine 
benchmark, examination of the nicotine dose-effect curves in the present study indicate that 
nicotine at 0.1 mg/kg or higher prompted responding comparable to the 0.4 mg/kg training 
dose. Future research will need to examine whether a higher dose of sazetidine-A can 
attenuate responding to these higher doses of nicotine.
The combination of 3 mg/kg nornicotine with sazetidine-A enhanced nicotine-like 
responding above that controlled by sazetidine-A alone. This effect was not seen at the 
higher dose of nornicotine (5.6 mg/kg) that prompted full substitution for nicotine when 
tested alone. Perhaps this decrease with 5.6 mg/kg nornicotine in the combination reflects 
partial antagonism by sazetidine-A. Our enthusiasm for this possibility is diminished by the 
lack of such an effect when the training dose of nicotine was used in the interaction test. 
Alternatively, when two compounds are tested together, the combination my produce 
stimulus effects that are distinct from either of the two drugs alone. These distinct stimulus 
elements may differ sufficiently from the training dose of nicotine, thus reducing responding 
in the test. The present study was not designed to examine this possibility. Future research 
will be needed to parse out potential neuropharmacological mechanisms contributing to the 
reduction in nicotine-like responding with the sazetidine-A plus 5.6 mg/kg nornicotine 
combination. Indeed, a similar possibility may explain the loss of conditioned responding at 
the higher doses of bupropion in combination of sazetidine-A; see also earlier discussion 
regarding locomotor effects of bupropion.
PNU-120596 is a selective positive allosteric modulator for the α7 nAChRs. As detailed 
earlier, PNU-120596 alone did not substitute for the nicotine stimulus. To determine if this 
lack of effect reflected insufficient ACh tone in key brain areas, we examined whether 
PNU-120596 would enhance partial generalization evoked by a low dose of nicotine (0.05 
mg/kg). Enhancement of conditioned responding was not evident at either dose of 
PNU-120596 tested in combination with nicotine. This outcome is consist with the present 
work and published studies indicating that the α7 nAChR does not play a role in generating 
the nicotine stimulus (Brioni et al, 1996; Van Haaren et al, 1999; Struthers et al, 2009; 
Zaniewska et al, 2006).
Women on average take less time than men to become dependent, make fewer attempts to 
quit smoking, remain abstinent for less time, have a higher relapse rate, and show less 
benefit from nicotine replacement therapy (Okene, 1993; Perkins and Scott, 2008; Perkins, 
2001; Schnoll et al, 2007). Research from animals models often corroborate these effects 
providing support for the assertion that some sex differences are rooted in biology (Harrod et 
al, 2004; Torres and O’Dell, 2016). As described in the Introduction and reviewed in Bevins 
and Charntikov (Bevins and Charntikov, 2015), until now, there has not been a single 
published study that we could find that used nicotine as the training stimulus and explicitly 
investigated sex differences. Overall, female rats, like their male counterparts, readily learn a 
discrimination between nicotine and saline, display a dose-dependent nicotine generalization 
curve, show substitution patterns as expected from published studies, and, importantly, do 
not show excessive variability as lab lore might suggest (cf. Prendergast et al, 2014). Clearly 
much more research is needed in this area and the present research provides investigators 
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with a strong beginning regarding the nature of the nicotine stimulus and the import of sex 
as a biological variable.
Acknowledgments
This work was in part supported by NIH research grant DA018114 and DA034389. All MED-PC programs used in 
the present article are available upon request.
References
Arnold AP. Mouse models for evaluating sex chromosome effects that cause sex differences in non-
gonadal tissues. J Neuroendocrinol. 2009; 21:377–386. [PubMed: 19207816] 
Beery AK, Zucker I. Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev. 2011; 
35:565–572. [PubMed: 20620164] 
Benowitz NL. Importance of Nicotine Metabolism in Understanding the Human Biology of Nicotine. 
Eff Nicotine Biol Syst. 1991; :19–24. DOI: 10.1007/978-3-0348-7457-1_3
Besheer J, Palmatier MI, Metschke DM, Bevins RA. Nicotine as a signal for the presence or absence 
of sucrose reward: A Pavlovian drug appetitive conditioning preparation in rats. 
Psychopharmacology (Berl). 2004; 172:108–117. [PubMed: 14530902] 
Bevins RA, Besheer J, Pickett KS. Nicotine-conditioned locomotor activity in rats: Dopaminergic and 
GABAergic influences on conditioned expression. Pharmacol Biochem Behav. 2001; 68:135–145. 
[PubMed: 11274718] 
Bevins RA, Caggiula AR. Nicotine, tobacco use, and the 55th Nebraska symposium on motivation. 
Nebraska Symp Motiv. 2009; 55:1–3.
Bevins RA, Charntikov S. We know very little about the subjective effects of drugs in females. ACS 
Chem Neurosci. 2015; 6:359–361. [PubMed: 25627010] 
Boakes RA. Performance on learning to associate a stimulus with positive reinforcement. Operant 
Interact. 1977:67–97.
Booze RM, Welch MA, Wood ML, Billings KA, Apple SR, Mactutus CF. Behavioral sensitization 
following repeated intravenous nicotine administration: Gender differences and gonadal hormones. 
Pharmacol Biochem Behav. 1999; 64:827–839. [PubMed: 10593207] 
Brioni JD, Kim DJB, O’Neill AB. Nicotine cue: lack of effect of the α7 nicotinic receptor antagonist 
methyllycaconitine. Eur J Pharmacol. 1996; 301:1–5. [PubMed: 8773440] 
Brunzell DH, Picciotto MR. The Motivational Impact of Nicotine and its Role in Tobacco Use: 
Chapter 3: Molecular Mechanisms Underlying the Motuivational Effects of Nicotine. Nebraska 
Symp Motiv. 2009; 55:17–30.
Cahill L. Why sex matters for neuroscience. Nat Rev Neurosci. 2006; 7:477–484. [PubMed: 
16688123] 
Centers for Disease Control and Prevention. Smoking -attributable mortality, years of potential life 
lost, and productivity losses --United States, 2000–2004. Mmwr. 2008; 57:1226–1228. [PubMed: 
19008791] 
Chaudhri N, Caggiula AR, Donny EC, Booth S, Gharib MA, Craven LA, et al. Sex differences in the 
contribution of nicotine and nonpharmacological stimuli to nicotine self-administration in rats. 
Psychopharmacology (Berl). 2005; 180:258–266. [PubMed: 15682294] 
Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant 
bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol 
Exp Ther. 1980; 215:127–34. [PubMed: 6778989] 
Damaj MI, Creasy KR, Welch SP, Rosecrans JA, Aceto MD, Martin BR. Comparative pharmacology 
of nicotine and ABT-418, a new nicotinic agonist. Psychopharmacology (Berl). 1995; 120:483–
490. [PubMed: 8539331] 
Desai RI, Barber DJ, Terry P. Asymmetric generalization between the discriminative stimulus effects 
of nicotine and cocaine. Behav Pharmacol. 1999; 10:647–656. [PubMed: 10780506] 
Charntikov et al. Page 13
Neuropharmacology. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Desai RI, Barber DJ, Terry P. Dopaminergic and cholinergic involvement in the discriminative stimulus 
effects of nicotine and cocaine in rats. Psychopharmacology (Berl). 2003; 167:335–43. [PubMed: 
12684733] 
Donny EC, Caggiula AR, Rowell PP, Gharib MA, Maldovan V, Booth S, et al. Nicotine self-
administration in rats: Estrous cycle effects, sex differences and nicotinic receptor binding. 
Psychopharmacology (Berl). 2000; 151:392–405. [PubMed: 11026746] 
Dwoskin LP, Wooters TE, Sumithran SP, Siripurapu KB, Joyce BM, Lockman PR, et al. N,N’-Alkane-
diyl-bis-3-picoliniums as Nicotinic Receptor Antagonists: Inhibition of Nicotine-Evoked 
Dopamine Release and Hyperactivity. J Pharmacol Exp Ther. 2008; 326:563–576. [PubMed: 
18460644] 
Farwell B, Ayres J. Stimulus-reinforcer and response-reinforcer relations in the control of conditioned 
appetitive headpoking (“goal tracking”) in rats. Learn Motiv. 1979; 10:295–312.
Ghosheh O, Dwoskin LP, Li WK, Crooks PA. Residence times and half-lives of nicotine metabolites in 
rat brain after acute peripheral administration of [2’-(14)C]nicotine. Drug Metab Dispos. 1999; 
27:1448–55. [PubMed: 10570026] 
Goldberg SR, Risner ME, Stolerman IP, Reavill C, Garcha HS. Nicotine and some related compounds: 
effects on schedule-controlled behaviour and discriminative properties in rats. 
Psychopharmacology (Berl). 1989; 97:295–302. [PubMed: 2497478] 
Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, et al. The subtypes of 
nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem 
Pharmacol. 2007; 74:1235–1246. [PubMed: 17825262] 
Haaren F, Van Anderson KG, Haworth SC, Kem WR. GTS-21, A mixed nicotinic receptor agonist/
antagonist, does not affect the nicotine cue. Pharmacol Biochem Behav. 1999; 64:439–444. 
[PubMed: 10515327] 
Harrod SB, Mactutus CF, Bennett K, Hasselrot U, Wu G, Welch M, et al. Sex differences and repeated 
intravenous nicotine: Behavioral sensitization and dopamine receptors. Pharmacol Biochem Behav. 
2004; 78:581–592. [PubMed: 15251267] 
Johnson JE, Slade S, Wells C, Petro A, Sexton H, Rezvani AH, et al. Assessing the effects of chronic 
sazetidine-A delivery on nicotine self-administration in both male and female rats. 
Psychopharmacology (Berl). 2012; 222:269–276. [PubMed: 22297831] 
Jung ME, Wallis CJ, Gatch MB, Lal H. Sex differences in nicotine substitution to a pentylenetetrazol 
discriminative stimulus during ethanol withdrawal in rats. Psychopharmacology (Berl). 2000; 
149:235–40. [PubMed: 10823403] 
Jutkiewicz EM, Brooks EA, Kynaston AD, Rice KC, Woods JH. Patterns of nicotinic receptor 
antagonism: nicotine discrimination studies. J Pharmacol Exp Ther. 2011; 339:194–202. [PubMed: 
21730011] 
Kanýt L, Stolerman IP, Chandler CJ, Saigusa T, Pögün a. Influence of sex and female hormones on 
nicotine-induced changes in locomotor activity in rats. Pharmacol Biochem Behav. 1999; 62:179–
187. [PubMed: 9972862] 
Kumar R, Reavill C, Stolerman IP. Nicotine cue in rats: effects of central administration of ganglion-
blocking drugs. Br J Pharmacol. 1987; 90:239–246. [PubMed: 2880625] 
LeSage MG, Shelley D, Ross JT, Carroll FI, Corrigall WA. Effects of the nicotinic receptor partial 
agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. 
Pharmacol Biochem Behav. 2009; 91:461–467. [PubMed: 18817808] 
Levin ED, Rezvani AH, Xiao Y, Slade S, Cauley M, Wells C, et al. Sazetidine-A, a Selective 42 
Nicotinic Receptor Desensitizing Agent and Partial Agonist, Reduces Nicotine Self-
Administration in Rats. J Pharmacol Exp Ther. 2010; 332:933–939. [PubMed: 20007754] 
Mogg AJ, Jones FA, Pullar IA, Sharples CGV, Wonnacott S. Functional responses and subunit 
composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-
A-85380. Neuropharmacology. 2004; 47:848–859. [PubMed: 15527819] 
Murray JE, Bevins RA. Acquired appetitive responding to intravenous nicotine reflects a Pavlovian 
conditioned association. Behav Neurosci. 2009; 123:97–108. [PubMed: 19170434] 
Charntikov et al. Page 14
Neuropharmacology. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Murray JE, Penrod RD, Bevins RA. Nicotine-evoked conditioned responding is dependent on 
concentration of sucrose unconditioned stimulus. Behav Processes. 2009; 81:136–139. [PubMed: 
19429207] 
Murray JE, Walker AW, Polewan RJ, Bevins RA. An examination of NMDA receptor contribution to 
conditioned responding evoked by the conditional stimulus effects of nicotine. 
Psychopharmacology (Berl). 2011; 213:131–141. [PubMed: 20859617] 
National Institute on Drug Abuse. Research Report Series: Marijuana. 2016. 12-43422–18at 
<www.drugabuse.gov/publications/research-reports/tobacco-addiction>
Nielsen JA, Shannon NJ, Bero L, Moore KE. Effects of acute and chronic bupropion on locomotor 
activity and dopaminergic neurons. Pharmacol Biochem Behav. 1986; 24:795–799. [PubMed: 
3086903] 
Okene JK. Smoking among women accross the life span: Prevalence, interventions and implications 
for cessation research. Ann Behav Med. 1993; 15:135–148.
Papke RL, Dwoskin LP, Crooks PA. The pharmacological activity of nicotine and nornicotine on 
nAChRs subtypes: Relevance to nicotine dependence and drug discovery. J Neurochem. 2007; 
101:160–167. [PubMed: 17241116] 
Perkins, Ka; Scott, J. Sex differences in long-term smoking cessation rates due to nicotine patch. 
Nicotine Tob Res. 2008; 10:1245–1251. [PubMed: 18629735] 
Perkins KA. Nicotine discrimination in men and women. Pharmacol Biochem Behav. 1999; 64:295–
299. [PubMed: 10515305] 
Perkins KA. Smoking cessation in women - Special considerations. CNS Drugs. 2001; 15:391–411. 
[PubMed: 11475944] 
Perkins KA, Grobe JE, D’Amico D, Fonte C, Wilson AS, Stiller RL. Low-dose nicotine nasal spray 
use and effects during initial smoking cessation. Exp Clin Psychopharmacol. 1996; 4:157–165.
Prendergast BJ, Onishi KG, Zucker I. Female mice liberated for inclusion in neuroscience and 
biomedical research. Neurosci Biobehav Rev. 2014; 40:1–5. [PubMed: 24456941] 
Reichel CM, Murray JE, Barr JD, Bevins RA. Extinction with varenicline and nornicotine, but not 
ABT-418, weakens conditioned responding evoked by the interoceptive stimulus effects of 
nicotine. Neuropharmacology. 2010; 58:1237–1245. [PubMed: 20302882] 
Rezvani AH, Slade S, Wells C, Petro A, Lumeng L, Li T-K, et al. Effects of sazetidine-A, a selective 
α4β2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-
administration in selectively bred alcohol-preferring (P) rats. Psychopharmacology (Berl). 2010; 
211:161–174. [PubMed: 20535453] 
Salminen O. Subunit Composition and Pharmacology of Two Classes of Striatal Presynaptic Nicotinic 
Acetylcholine Receptors Mediating Dopamine Release in Mice. Mol Pharmacol. 2004; 65:1526–
1535. [PubMed: 15155845] 
Schnoll R, Patterson F, Lerman C. Treating Tobacco Dependence in Women. J Women’s Heal. 2007; 
16:1211–1218.
Shoaib M, Sidhpura N, Shafait S. Investigating the actions of bupropion on dependence-related effects 
of nicotine in rats. Psychopharmacology (Berl). 2003; 165:405–412. [PubMed: 12451438] 
Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P, et al. Ligands selective for α4β2 but not 
α3β4 or α7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. 
Psychopharmacology (Berl). 2007; 190:157–170. [PubMed: 17115136] 
Stolerman IP, Chamberlain S, Bizarro L, Fernandes C, Schalkwyk L. The role of nicotinic receptor α7 
subunits in nicotine discrimination. Neuropharmacology. 2004; 46:363–371. [PubMed: 14975691] 
Stolerman IP, Smith JW, Stolerman IP. Recognising nicotine: The neurobiological basis of nicotine 
discrimination. Handb Exp Pharmacol. 2009; 192:295–333.
Struthers AM, Wilkinson JL, Dwoskin LP, Crooks PA, Bevins RA. Mecamylamine, dihydro-β-
erythroidine, and dextromethorphan block conditioned responding evoked by the conditional 
stimulus effects of nicotine. Pharmacol Biochem Behav. 2009; 94:319–328. [PubMed: 19778551] 
Tanoue LT. Quitting Smoking Among Adults — United States, 2001–2010. Yearb Pulm Dis. 2012; 
2012:72–74.
Charntikov et al. Page 15
Neuropharmacology. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Thompson DM, Moerschbaecher JM, Winsauer PJ. Drug effects on repeated acquisition: comparison 
of cumulative and non-cumulative dosing. J Exp Anal Behav. 1983; 39:175–184. [PubMed: 
6833939] 
Torres OV, Natividad LA, Tejeda HA, Weelden SA, Van O’Dell LE. Female rats display dose-
dependent differences to the rewarding and aversive effects of nicotine in an age-, hormone-, and 
sex-dependent manner. Psychopharmacology (Berl). 2009; 206:303–312. [PubMed: 19629450] 
Torres OV, O’Dell LE. Stress is a principal factor that promotes tobacco use in females. Prog Neuro-
Psychopharmacology Biol Psychiatry. 2016; 65:260–268.
Wetherington CL. Sex-gender differences in drug abuse: A shift in the burden of proof? Exp Clin 
Psychopharmacol. 2007; 15:411–417. [PubMed: 17924775] 
Wiley JL, LaVecchia KL, Martin BR, Damaj MI. Nicotine-like discriminative stimulus effects of 
bupropion in rats. Exp Clin Psychopharmacol. 2002; 10:129–135. [PubMed: 12022798] 
Wilkinson J, Carroll F, Bevins R. An investigation of bupropion substitution for the interoceptive 
stimulus effects of nicotine. J Psychopharmacol. 2010; 24:817–828. [PubMed: 19304864] 
Wilkinson JL, Li C, Bevins RA. Pavlovian drug discrimination with bupropion as a feature positive 
occasion setter: Substitution by methamphetamine and nicotine, but not cocaine. Addict Biol. 
2009; 14:165–173. [PubMed: 19076926] 
Wooters TE, Bevins RA, Bardo MT. Neuropharmacology of the Interoceptive Stimulus Properties of 
Nicotine. Curr Drug Abus Rev. 2009; 2:243–255.
Xiao, Y.; Woolverton, W.; Sahibzada, N.; Yasuda, R.; Kellar, K. Pharmacological properties of 
sazetidine-A, a desensitizer of alpha4beta2 nicotinic acetylcholine receptors. San Diego Neurosci 
Meet Planner; 2007; 2007. Progr No 5746/J11
Young R, Glennon RA. Nicotine and bupropion share a similar discriminative stimulus effect. Eur J 
Pharmacol. 2002; 443:113–118. [PubMed: 12044800] 
Zaniewska M, McCreary AC, Przegaliński E, Filip M. Evaluation of the role of nicotinic acetylcholine 
receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. 
Eur J Pharmacol. 2006; 540:96–106. [PubMed: 16730696] 
Zwart R, Carbone AL, Moroni M, Bermudez I, Mogg AJ, Folly Ea, et al. Sazetidine-A Is a Potent and 
Selective Agonist at Native and Recombinant 42 Nicotinic Acetylcholine Receptors. Mol 
Pharmacol. 2008; 73:1838–1843. [PubMed: 18367540] 
Charntikov et al. Page 16
Neuropharmacology. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
• Stimulus effects of nicotine were assessed in female and male rats
• Nicotine-saline discrimination trained using the discriminated goal-
tracking task
• Substitution ligands were potential pharmacotherapies or nAChR-
binding compounds
• Overall, substitution was similar in female and male rats across the 
tests
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Fig. 1. 
A graphical representation of the testing order for each Set of rats used in this study.
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Fig. 2. 
Data from the discrimination training phase represented as a mean (±SEM) number of 
dipper entries per second during 2 min prior to initial sucrose or equivalent in timing during 
no reward presentations. (A) Acquisition of discrimination from Set 1 and (B) Set 
2. *Denotes sessions with significant differences between saline and nicotine evoked 
responding. #Denotes overall differences in responding during discrimination training phase.
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Fig. 3. 
A mean (±SEM) number of total dipper entries for each nicotine dose-effect curves. (A, B, 
and C) Data from dose-effect curves 1–3. (D) Data from cumulative dose-effect curve. 
*Denotes significant difference of combined female and male responding from 0 mg/kg dose 
(saline).
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Fig. 4. 
A mean (±SEM) number of total dipper entries for substitution tests with (A) sazetidine-A, 
(B) PHA, (C) PNU, (D) bupropion, (E) nornicotine, and (F) cytisine. *Denotes significant 
difference of combined female and male responding from 0 mg/kg dose (saline).
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Fig. 5. 
A box-plot showing a magnitude of responding from the selected doses of each substitution 
ligand that evoked the highest responding during substitution tests. A black dot within the 
boundaries of the box represents a mean responding for each particular ligand with the 
actual mean number indicated above that dot. Scattered grey dots and open triangles 
represent individual responding of females and males (respectively) for each ligand 
tested. ##Denotes full substitution for the nicotine stimulus. #Denotes partial substitution for 
the nicotine stimulus.
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Fig. 6. 
A mean (±SEM) number of total dipper entries from combination tests with (A) sazetidine-
A and nicotine, (B) sazetidine-A and bupropion, (C) sazetidine-A and nornicotine, (D) 
sazetidine-A and cytisine, (E) nicotine and PNU. Point size plotted on panels B and D 
represents general chamber activity for each tested combination and does not represent 
proportional change in locomotor activity.
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TABLE 1
Drug Information
†All drugs, except PNU-120596, were administered at 1 mg/ml volume and were diluted in saline; PNU- 120596 was administered at 0.5 mg/ml 
and was dissolved in 10% Tween prepared in H2O.
1
Denotes tests on the first subset of rats.
2
Denotes tests using the second subset of rats. Interaction tests are indicated by the brackets (interaction doses in bold; also cf. Figure 1).
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